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IgM antibodies. Often, there will be chorioretinal scars, and
reactivation can occur on the edge of a previous lesion, making
diagnosis easier. However, the active area can cover a scar,
particularly if it is small, making it difficult to see the original
scar. Rising titers of IgG do not occur with ocular reactivation.
There is increasing evidence that patients acquire this infection
postnatally rather than by congenital transmission [18], and it is
not yet known whether the most common source of infection is
undercooked infected meat [19] or cats [20].
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Please refer to the article on pages 637–638 of this issue to view
the questions to which these answers refer.
1. Oropharyngeal tularemia. This clinical case may be confused
with other infectious and non-infectious diseases affecting
cervical lymph nodes, such as streptococcal angina, infectious
mononucleosis, tuberculosis and lymphoma [1].
2. Oropharyngeal tularemia results from ingestion of poten-
tially infected animals or fruits (hare, strawberries); however,
sometimes there is no risk factor present (68.5%) [1,2]. In our
case, the patient and his mother had no previous history of tick
bite, and the possible routes were direct contact (skinning by
hand) and inhalation. Both of them had skinned a wild boar, but
the incubation period was too long for this to be the cause, and
neither of them had had wounds or ulcers on their hands. They
also denied having eaten other wild animals, river crabs or wild
fruits, or having drunk water from springs. The similarity of the
clinical picture in the patient and his mother suggested a
common source of infection, but its etiology could not be
established.
3. The laboratory diagnosis is generally based on the positivity
of agglutinating antibodies to Francisella tularensis. Our patient
developed seroconversion with a maximum titer of 1 : 2560.
Another microbiological technique for the diagnosis of tular-
emia is PCR [3]. In this case, a sample of the fluid obtained was
positive for F. tularensis by PCR (performed by Dr Pedro Anda,
Instituto Carlos III, Spain).
4. Because F. tularensis antibodies may cross-react with Brucella
sp., as well as with other microorganisms such as Proteus OX19
and Yersinia sp. [2,4].
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5. Treatment is usually empirical. Streptomycin is the drug of
choice, although the percentage of cure of tularemia with
streptomycin and gentamicin is similar [5]. Therapy must be
continued for 10–14 days, but the duration of the fever is the
best indicator of response [2,5]. Because our patient declined
therapy with intramuscular streptomycin, treatment with intra-
venous gentamicin was started (6 mg/kg per day, divided every
8 h, for 14 days).
DISCUSSION
Tularemia is caused by F. tularensis, a small, Gram-negative
coccobacillus. Two main types of F. tularensis have been
described, type A and type B, which have differences in their
epidemiology and virulence. Type A is the predominant biovar
found in North America; type B, a less virulent biovar, occurs in
Europe, Asia and North America [6]. In Spain, this is a rare
illness with sporadic reports, with the exception of a recent
epidemic tularemia outbreak in Valladolid [7].
The most important reservoirs are hares and ticks, although
other wild animal can be reservoirs of this illness. It is trans-
mitted to human by tick bite, direct contact with infected
animals (skinning of dead animals), and inhalation and ingestion
of contaminated water or food [1,2,8]. A bimodal distribution
of cases has been described. Tick-associated disease occurs from
May to September, whereas rabbit-associated disease is most
common from November to February [2].
The clinical presentation depends on the route of inoculation
and the lymphadenopathy is used to determine the site and
mode of inoculation. After mammal exposure, 65% of lym-
phadenopathy occurred in the axilla; but after tick bite, 64% of
lymphadenopathy occurred in the inguinal area. Because there
was no previous tick bite history in our patient, the possible
routes were skinning and inhalation. Oropharyngeal tularemia
is due to ingestion of potentially infected animals or fruits (hare,
strawberries) or contaminated water ingestion; however, some-
times there is no risk factor present (68.5%) [1,2,8].
Six classical forms of tularemia have been described in
humans, based on clinical presentation of the illness: ulcero-
glandular, glandular, oculoglandular, oropharyngeal, typhoideal
and pneumonic [2,9]. The most common clinical form of
tularemia is ulceroglandular, with a primary ulcer on the skin
and corresponding regional lymphadenopathy. Glandular tular-
emia, in which no primary ulcer is seen, is less common [1,2,7].
Among all the clinical pictures of tularemia, oropharyngeal
tularemia appears to represent about 3% [1]. It is possible that
this type of tularemia, without other manifestations, could
remain undiagnosed, and its diagnosis is more a fortuitous
finding than a primary suspicion [8]. In Spain, during the
report of the first 65 cases of an epidemic tularemia outbreak
in Valladolid, no cases of oropharyngeal tularemia were diag-
nosed [7].
The usual incubation period is 3–5 days (range, 1–21 days).
Tularemia usually begins abruptly. Fever, chills, headache,
malaise, anorexia and fatigue are quite common. Persistent
lymphadenopathy could be present for a long time, even years,
without appropriate treatment [1,2]. About 50% of patients
have a history of sore throat, but, on examination, this is not
clinically infected. These patients are often referred to a spe-
cialist, because the symptoms do not subside with b-lactam
antibiotics [1].
Laboratory parameters are unremarkable [2]. The laboratory
diagnosis is generally based on the positivity of agglutinating
antibodies to F. tularensis. A fourfold increase in titer between
two determinations is considered to be diagnostic, but a single
titer of 1 : 160 or higher in a patient suspected of tularemia is
very suggestive. Because of the infectious risk for laboratory
workers, routine culture of F. tularensis is not indicated. When
there is a suspicion of tularemia, laboratory workers should be
notified. Another useful microbiological technique for the
diagnosis of tularemia is PCR [3], but this is not available in
all laboratories.
F. tularensis antibodies may cross-react with Brucella sp.,
Proteus OX19 and Yersinia sp. [2,4]. In patients with tularemia,
slide tests for heterophilic antibodies (Monotest) may be posi-
tive. Therefore, cases of oropharyngeal tularemia may be mis-
diagnosed as mononucleosis if the tularemia agglutination titer
is not determined [1,2].
If a biopsy specimen (node or abscess) shows a combination
of abscess and caseous type of necrosis with an infiltration of
numerous polymorphonuclear leukocytes, tularemia should be
considered [1].
Treatment is usually empirical. Streptomycin is the drug of
choice (1 g every 12 h IM for 7–14 days). The percentages of
cure of tularemia with streptomycin and gentamicin are 97%
and 86%, respectively. Additional factors could have contrib-
uted to failure in gentamicin therapy (i.e. inclusion of severe
illness or presence of underlying diseases), so the efficacies of
streptomycin and gentamicin are similar against tularemia [5].
The therapy must be continued for 10–14 days, but the duration
of the fever is the best indicator of response [2,5]. During
pregnancy and when the use of streptomycin is not possible,
gentamicin is an effective alternative. The use of once-daily
gentamicin for the treatment of tularemia has been suggested,
but there is little evidence available, so further studies will be
necessary to determine its efficacy. Other alternative regimens
are doxycycline, quinolones (ciprofloxacin), and even imipe-
nem–cilastatin [5,7].
In areas where tularemia has been described, this should be
included among differential diagnoses of oropharyngeal infec-
tion when b-lactam antibiotics are not successful [1,8].
Chemoprophylaxis for risk groups is not recommended, and
antibiotic prophylaxis after tick bite is not indicated. Avoiding
exposure to the microorganism is the best way to prevent
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tularemia (not skinning or dressing the animal without gloves,
mask and glasses, avoiding tick bites, and removing ticks as
quickly as possible with tweezers) [2].
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